Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

PURPOSE: This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy. PATIENTS AND METHODS: A total of 1,538 patients with resected pT2 (high grade) or ≥ pT3, including N1,...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Motzer, Robert J., Haas, Naomi B., Donskov, Frede, Gross-Goupil, Marine, Varlamov, Sergei, Kopyltsov, Evgeny, Lee, Jae Lyun, Melichar, Bohuslav, Rini, Brian I., Choueiri, Toni K., Zemanova, Milada, Wood, Lori A., Reaume, M. Neil, Stenzl, Arnulf, Chowdhury, Simon, Lim, Ho Yeong, McDermott, Ray, Michael, Agnieszka, Bao, Weichao, Carrasco-Alfonso, Marlene J., Aimone, Paola, Voi, Maurizio, Doehn, Christian, Russo, Paul, Sternberg, Cora N.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2017
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6018511/
https://ncbi.nlm.nih.gov/pubmed/28902533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.5324
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk